Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $11.38

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.38.

CMPX has been the topic of several recent analyst reports. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. Guggenheim began coverage on shares of Compass Therapeutics in a research report on Monday, February 24th. They issued a "buy" rating and a $12.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group lifted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th.

Institutional Trading of Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth about $35,000. Tang Capital Management LLC lifted its position in Compass Therapeutics by 225.4% during the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock worth $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after acquiring an additional 9,451 shares during the period. MPM Bioimpact LLC grew its position in Compass Therapeutics by 51.9% in the fourth quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after acquiring an additional 2,926,002 shares in the last quarter. Finally, Enavate Sciences GP LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at approximately $11,293,000. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Compass Therapeutics Trading Up 6.8 %

Shares of NASDAQ CMPX traded up $0.16 during midday trading on Friday, reaching $2.53. 909,918 shares of the stock were exchanged, compared to its average volume of 649,666. The company has a market capitalization of $349.86 million, a P/E ratio of -6.84 and a beta of 1.19. The stock has a 50 day moving average price of $2.73 and a 200-day moving average price of $2.02. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.